| 米氮平治疗躯体形式障碍临床研究 |
| |
| 引用本文： | 邹慧,王震,杨瑞兰.米氮平治疗躯体形式障碍临床研究[J].临床心身疾病杂志,2006,12(1):28-29. |
| |
| 作者姓名： | 邹慧 王震 杨瑞兰 |
| |
| 作者单位： | 1. 453000,河南·新乡,新乡市第一人民医院
2. 新乡医学院第二附属医院 |
| |
| 摘 要： | 目的探讨米氮平治疗躯体形式障碍的临床疗效。方法对36例躯体形式障碍患者给予米氮平治疗,剂量30mg· d-1·qn。疗程4w。于治疗前及治疗4w末采用抑郁自评量表评定临床疗效;治疗前后对躯体症状进行分级评定分析。结果治疗前后抑郁自评量表评分比较差异有显著性(P<0．05),临床总显效率85．6％;躯体症状较治疗前有显著性改善(P<0． 05)。结论米氮平治疗躯体形式障碍疗效确切,不失为一种治疗躯体形式障碍较为理想的药物。
|
| 关 键 词： | 躯体形式障碍 抑郁自评量表 米氮平 |
| 文章编号： | 1672-187X（2006）01-028-02 |
| 收稿时间： | 2005-05-23 |
| 修稿时间： | 2005年5月23日 |
Clinical studies of mirtazapine in the treatment of somatoform disorder |
| |
| Zou Hui,Wang Zhen,Yang Ruilan.Clinical studies of mirtazapine in the treatment of somatoform disorder[J].Journal of Clinical Psychosomatic Diseases,2006,12(1):28-29. |
| |
| Authors: | Zou Hui Wang Zhen Yang Ruilan |
| |
| Abstract: | Objective To explore clinical effectiveness of mirtazapine in the treatment of somatoform disorders. Methods 36 patients with somatoform disorders were treated with mirtazapine, 30mg/d for 4weeks. Clinical effectiveness was assessed with the Self-rating Depression Scale(SDS) and somato-symptoms were assessed and analyzed before treatment and at the end of 4th treatment. Results There was significant difference in the SDS between pre-and post-treatment(P<0. 05) , clinical effectual rate was 85. 6% ; after treatment, somato-symptoms significantly improved(P<0. 05). Conclusion Mirtazapine is effective and more ideal in the treatment of somato-symptoms. |
| |
| Keywords: | Somatoform disorders SDS mirtazapine |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
